What Is Glucagon? And Why Obesity Drugs Use It

What is glucagon? Glucagon is a 29-amino-acid hormone peptide that raises blood sugar when fuel runs low. Obesity drugs pair its receptor signal with GLP-1, and sometimes GIP, because glucagon may raise energy expenditure and help clear liver fat while the other hormone arms restrain appetite and glucose.

What does glucagon do in the body?

Glucagon keeps fuel available between meals by telling the liver to release glucose. Alpha cells in the pancreas make this glucagon hormone peptide when blood sugar falls, during fasting, and in other low-fuel states. Insulin generally moves glucose out of the blood; glucagon supplies more. They are opposing controls, not good and bad hormones.

Glucagon reaches receptors concentrated in the liver. The liver then breaks glycogen, its stored carbohydrate, back into glucose and makes new glucose from other raw materials. That answers the everyday version of what does glucagon do: glucagon stops blood sugar from drifting too low when food is not arriving.

Manufactured glucagon uses the same basic biology. The current DailyMed prescribing information covers severe hypoglycemia and use as a diagnostic aid. That rescue medicine is different from an obesity drug engineered to provide sustained, balanced activity at several hormone receptors.

Why activate a hormone that raises blood sugar for weight loss?

Obesity-drug designers activate glucagon because blood sugar is only one part of its metabolic job. Glucagon also changes how the body spends fuel and how the liver handles fat. The catch is obvious: turn that signal up alone and glucose rises. Pairing glucagon with GLP-1, and sometimes GIP, is meant to keep the useful metabolic push while countering the glucose excursion and reducing food intake.

The glucagon receptor agonist weight loss idea is therefore a balancing act. GLP-1 supplies strong appetite and glucose control. The glucagon arm is intended to add energy use and liver-directed fat metabolism. A combination molecule is less like pressing one accelerator and more like tuning three linked controls. The ratios matter, which is why one successful drug does not validate every glucagon-containing design.

Does human evidence show that glucagon raises energy expenditure?

Human evidence shows that acute glucagon administration raises energy expenditure, but it does not yet prove how much sustained glucagon activity contributes to long-term weight loss. A systematic review found 15 randomized crossover studies in adults without diabetes. Five energy-expenditure studies included 59 participants, so this is human evidence with a small base, not a settled chronic-treatment result.

The 2022 meta-analysis found a moderate-to-large pooled increase in energy expenditure after acute glucagon, alongside increases in glucose and insulin. Food-intake results were unclear, and every included study had some risk-of-bias concern. That places the evidence in two honest tiers: direct human support for an acute energy-use effect, but mechanistic inference for how much that effect drives months of weight loss on a multi-receptor drug.

Why did glucagon antagonist trials change the field?

Glucagon antagonist trials supplied a useful reverse experiment: blocking the receptor lowered blood sugar but pushed liver fat and body weight in the wrong direction. That result made glucagon look less like metabolic noise and more like a lever worth preserving. Reverse experiments are rarely glamorous, but failed drug programs can teach cleaner biology than a stack of diagrams.

In a six-month randomized trial, 174 adults with type 2 diabetes received the glucagon receptor antagonist LY2409021, placebo, or sitagliptin. LY2409021 lowered HbA1c versus placebo, yet hepatic fat fraction increased by 4.44 percentage points versus placebo. Body weight and total cholesterol also increased significantly, and liver enzymes rose. The effects were reversible.

That trial does not prove the mirror image, that receptor activation must remove the same amount of fat or weight. It does show a real human tradeoff: blocking glucagon improved glucose while worsening several lipid and weight measures. The obesity field responded by trying to pair glucagon’s metabolic effects with incretin hormones that handle its glucose liability.

What does the glucagon arm add to retatrutide?

The triple agonist glucagon arm is designed to add energy expenditure and liver-fat clearance to retatrutide’s GIP and GLP-1 effects. Human results support the whole molecule, not a clean percentage contribution from each receptor. Retatrutide has no matched version with only its glucagon activity removed, so claims that the third arm “caused” a specific amount of weight loss go beyond the trial.

The clearest liver result came from a randomized phase 2a substudy of 98 participants with obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). At 24 weeks, mean relative liver-fat change reached -81.4% with 8 mg and -82.4% with 12 mg, versus +0.3% with placebo. Liver-fat reductions tracked with weight, abdominal fat, and metabolic improvements, so the study cannot separate direct glucagon action from weight loss and the other receptor arms.

Retatrutide is the triple agonist. Survodutide and mazdutide pair glucagon with GLP-1 instead. Phase 2 randomized trials found weight loss with both survodutide and mazdutide, which strengthens the class signal while still leaving each molecule’s receptor balance to stand on its own data.

Is glucagon approved for weight loss?

Glucagon itself is FDA-approved in specific products for severe hypoglycemia and diagnostic use, not as a weight-loss treatment. Retatrutide, survodutide, and mazdutide are not FDA-approved for weight management in the United States as of July 2026. FDA has identified products sold online under all three names as unapproved new drugs.

The FDA warning letter naming the three compounds also makes a practical distinction: “research use only” on a storefront does not turn an investigational molecule into an approved medicine. The science is advancing quickly; the U.S. product status is much less ambiguous.

So, what is glucagon in the obesity-drug story? Glucagon is the deliberately difficult arm: it can raise glucose, yet human evidence also ties the pathway to energy expenditure, body weight, and liver fat. The credible case comes from combinations and converging experiments, not from pretending a blood-sugar-raising hormone somehow stopped raising blood sugar.